Document:

Agreement between ImmunoCellular Therapeutics, Ltd. and C. Kirk Peacock

 EXHIBIT 10.1 
 ImmunoCellular Therapeutics, Ltd. 
 1999
Avenue of the Stars, 11th Floor, 
 Los
Angeles, California 90067 
 November 5, 2007 
 Mr. C. Kirk Peacock 
 20 Salida del Sol 
 Santa Barbara, CA 93109 
 Dear Kirk:

 This letter outlines the basis upon which ImmunoCellular Therapeutics, Ltd. (the “Company”) will engage you as its Interim
President and will continue to engage you as its Chief Financial Officer. 
 1. Engagement. You will be engaged as Interim
President and Chief Financial Officer of the Company for the term and upon the terms and conditions set forth herein, and you accept such offer of engagement. As the Interim President, your duties will include the signing of all of the
Company’s filings with the Securities and Exchange Commission (the “SEC”) as the Company’s principal executive officer and such other specific executive responsibilities as shall be agreed to by the Company and you in writing
subsequent to the date of this Agreement. As the Company’s Chief Financial Officer, your duties shall consist primarily of (i) the timely filing of all SEC filings, including preparing drafts of financial statements and the MD&A
portions of the Company’s Form 10-KSB and drafts of the Company’s Form 10-QSB and review of the Company’s registration statement disclosures; (ii) implementation and maintenance of the Company’s Sarbanes-Oxley
compliance procedures and confirming accounting compliance under Sarbanes-Oxley on a quarterly basis; (iii) preparation of annual two-year budgets (segmented quarterly) for the Company; (iv) closing of the Company’s financial books on
a quarterly basis; (v) coordinating reviews and audits of the Company’s financial statements by the Company’s independent public accounting firm; and (vi) quarterly presentations to the Company’s board of directors of the
Company’s financial information, including quarterly budgets to actual. You will report to the Chairman of the Board of the Company as well as the Chairman of the Audit Committee of the Company. 
 2. Term. The term of your engagement will be through October 29, 2008, commencing October 30, 2007 as to your engagement as CFO
and November 5, 2007 as to your engagement as Interim President; unless sooner terminated by you or the Company as set forth below in Section 7. 
 3. Commitment/Part-time Status. For the compensation provided in Section 4, you will set aside and commit a minimum (on average) of one to two business days per week toward attending to the affairs
of the Company as the Interim President and Chief Financial Officer. If, after a reasonable period of time, you find that the time required to fulfill your duties exceeds one to two days per week (on average), then subsequent to your notification of
the latter finding, the Company and you agree to review the terms of your compensation structure and/or the nature of your duties and to make adjustments deemed necessary and appropriate. The Company recognizes and agrees that, due to your part-time
status, you may accept other employment or consulting assignments concurrent with your engagement by the Company, which may include employment as an officer of publicly-traded companies and/or employment 

 Mr. Kirk Peacock 
 November 5, 2007 
  Page
 2
 
  

 
by other companies engaged in biotech or pharmaceutical research and development, provided that you disclose such employment by any other company to the
Company and that such companies are not engaged in any research or development activities in the field of immunocellular therapies. 
 4.
Compensation. As payment in full for your services during the term of this Agreement, the Company shall grant to you options to purchase 50,000 shares of the Company’s common stock (the “New Options”), which shall vest
monthly pro rata over the one-year term of this Agreement and $8,000 per month. The cash compensation shall be paid monthly on the first business day of each month. The New Options will have a seven-year term commencing on the date of grant; will
have an exercise price of the last reported trading price of the Company’s common stock on the OTC Bulletin Board on November 5, 2007; will be exercisable within the term of those options during the period of your services to the Company
and for 24 months after termination for any reason except termination for cause by the Company; and will have such other terms and conditions as are included in the Company’s standard nonqualified stock option agreement under its 2006 Equity
Incentive Plan (the “Plan”). All of your outstanding options granted under the Plan will be included in the Company’s Form S-8 registration statement, which shall be filed with the SEC on or before November 9, 2007. 

5. Expenses. The Company will promptly reimburse you for all reasonable business expenses incurred by you in connection with the
business of the Company in accordance with regular Company policy regarding the nature and amount of expenses and the maintenance and submission of receipts and records necessary for the Company to document them as proper business expenses. These
expenses shall include, without limitation, out-of-pocket telephone, facsimile, office supplies and authorized travel expenses but shall not include rent, utilities or similar overhead expenses incurred by you to maintain your office space.

 6. Indemnity. To the extent permitted by California law, you agree to indemnify and hold the Company harmless from and
against any and all losses, damages, liabilities, costs, and expenses, including attorneys’ fees, arising from or attributable to or resulting from your gross negligence or willful misconduct in rendering the services. You warrant and represent
that you have full power and authority to enter into and perform this Agreement and that your performance of this Agreement will not violate the provisions of any other agreement to which you are a party. The Company agrees to indemnify and hold you
harmless from and against any and all claims, demands, causes of action, losses, damages, liability, costs and expenses, including attorneys fees arising out of your services hereunder, other than those arising from or attributable to or resulting
from your gross negligence or willful misconduct. The Company will name you as an officer on any policy of directors and officers liability insurance it secures throughout the term of your engagement. 
 7. Termination. This Agreement and your rights and obligations hereunder shall, under any of the following circumstances, terminate in
advance of the time specified in Section 2 above, and you shall have the right to receive only your compensation that shall be accrued hereunder through the effective date of such termination and shall have no right to receive any further
compensation hereunder from and after the time of such termination: 
 7.1 Death. This Agreement and your duties
hereunder shall terminate immediately upon your death. 

 Mr. Kirk Peacock 
 November 5, 2007 
  Page
 3
 
  

 7.2 Termination by the Company. The Company may, at its option,
terminate this Agreement and your duties hereunder by written notice to you at any time without cause upon 30 days written notice to you. If you are terminated without cause, in addition to all accrued compensation, the Company shall grant you 50%
of any unvested options as of the date of termination. The Company may terminate this Agreement for Cause (as hereinafter defined) at any time upon written notice to you. “Cause” as used in this Agreement means that you, (i) after
reasonable notice and warning, have failed to perform your assigned duties as defined in this Agreement, with such failure to be determined by the Board of Directors, (ii) have materially breached any of the terms or conditions of this
Agreement and have failed to correct such breach within 15 days following written notice from the Company of such breach, or (iii) have been charged with a felony or any intentionally fraudulent act that materially damages, or may materially
damage, the business or reputation of the Company. 
 7.3 Termination by the You. You may terminate this
Agreement at any time without cause upon 30 days written notice to the Company or upon written notice to the Company if the Company shall have materially breached any of the provisions of this Agreement and has failed to correct such breach within
15 days following written notice from you of such breach. 
 8. Arbitration. In the event of any dispute under this Agreement,
such dispute shall be resolved by binding arbitration with JAMS/ENDISPUTE in Los Angeles, California. The arbitrator shall be a retired judge with at least five years of experience on the bench. This provision shall not be interpreted so as to
require arbitration of claims that the state and/or Federal Courts of California have ruled may not be the subjects of compelled arbitration in employment matters, nor shall it be interpreted so as to restrict any remedy, right of appeal or
discovery device available to either party in a manner that violates the rulings of the state and/or Federal Courts of California with respect to employment-related arbitration. This provision shall not be interpreted so as to preclude the making of
reports to governmental offices, or to preclude either party from seeking injunctive or provisional relief in a court of appropriate jurisdiction under such circumstances as may merit such relief. This arbitration provision is inapplicable to claims
of less than $25,000. 
 9. Confidentiality. While this Agreement is in effect and for a period of five years thereafter, you
shall hold and keep secret and confidential all “trade secrets” (within the meaning of California law) and shall use such information only in the course of performing your duties hereunder; provided, however, that with respect to trade
secrets, you shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under California law. You shall maintain in trust all such trade secrets as the Company’s property, including, but not limited
to, all documents concerning the Company’s business, including your work papers, telephone directories, customer information and notes, and any and all copies thereof in your possession or under your control. Upon the expiration or earlier
termination of your employment with the Company, or upon request by the Company, you shall deliver to the Company all such documents belonging to the Company, including any and all copies in your possession or under your control. 
 10. Applicable Law. This Agreement shall be interpreted in accordance with the internal laws of the State of California. 

 Mr. Kirk Peacock 
 November 5, 2007 
  Page
 4
 
  

 We are delighted that you have agreed to serve as our Interim President and to continue with us as
Chief Financial Officer and look forward to working with you to make the Company a great success. 
 Very truly yours,

  

			
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	 By:
	 	 /s/    JOHN
YU        

		 	 Dr. John Yu,
 Chairman of the
Board

 Agreed to and
Accepted as of this 5th day of November 2007. 
 /s/ C. Kirk Peacock 
 C. Kirk PeacockForm of Intellectual Property Agreement

 Exhibit 10.10 
 INTELLECTUAL PROPERTY AGREEMENT 
 This Intellectual Property Agreement (the “Agreement”), is entered into
as of [                    ], 2007 (the “Effective Date”), by and between Morgan Stanley & Co. Incorporated, a Delaware
corporation (“MS”) and MSCI Inc., a Delaware corporation (“MSCI”). (MS and MSCI individually referred to as a “Party” and collectively as the “Parties”). 
  

	1.	DEFINITIONS 

  

	 	1.1	Certain Definitions. 

 As used in this
Agreement: 
  

	 	(a)	“Including” and its derivatives, each whether or not capitalized in this Agreement, means “including but not limited to”. 

  

	 	(b)	“Licensed Materials” means, as applicable, the MS Licensed Materials and the MSCI Licensed Materials. 

  

	 	(c)	“MS Licensed Materials” means collectively, to the extent owned by a member of the MS Provider Group, any hardware settings and configurations, generic software libraries
and routines, and generic document templates not separately commercialized by the MS Provider Group (as defined below) and used by MSCI prior to the Trigger Date. For the avoidance of doubt, the MS Licensed Materials does not include (i) any
patent, trademark or service mark of the MS Provider Group, or (ii) any infrastructure hardware or software (e.g., monitoring software and systems, customized operating systems (and components such as AFS, DNS, AD, etc.), and middleware). For
the avoidance of doubt, the document templates do not include any references to members of the MS Provider Group or its personnel. 

  

	 	(d)	“MSCI Licensed Materials” means collectively, to the extent owned by a member of the MSCI Provider Group, any hardware settings and configurations, generic software
libraries and routines, and generic document templates not separately commercialized by the MSCI Provider Group (as defined below) and used by MS prior to the Trigger Date. For the avoidance of doubt, the MSCI Licensed Materials does not include
(i) any patent, trademark or service mark of the MSCI Provider Group, (ii) any infrastructure hardware or software (e.g., monitoring software and systems, customized operating systems and middleware), or (iii) any software or data
separately licensed to MS by the MSCI Provider Group (such as the Barra Aegis software or the MSCI indices). For the avoidance of doubt, the document templates do not include any references to members of the MSCI Provider Group or its personnel.

  

	 	(e)	“Trigger Date” means the date upon which Morgan Stanley shall cease to own more than 50% of the issued and outstanding shares of MSCI common stock.

  

	 	1.2	Other Terms. 

 Other terms used in this
Agreement are defined in the context in which they are used and shall have the meanings there indicated. 

	2.	GRANT OF LICENSE 

  

	 	2.1	MS Grant. 

 MS hereby grants (subject to any
existing third party contractual obligations) to MSCI a non-exclusive, perpetual, irrevocable, world-wide, royalty-free license for MSCI to use, modify, copy, create derivative works of and sublicense, for any business purpose, the MS
Licensed Materials. 
  

	 	2.2	MSCI Grant. 

 MSCI hereby grants (subject to
any existing third party contractual obligations) to MS a non-exclusive, perpetual, irrevocable, world-wide, royalty-free license for MS to use, modify, copy, create derivative works of and sublicense, for any business purpose, the MSCI
Licensed Materials. 
  

	 	2.3	Internet and Subnet Addresses. 

 For the
avoidance of doubt, this Agreement does not address or affect any rights of the Parties in or to internet or subnet addresses. 
  

	3.	DELIVERY 

  

	 	3.1	No Support or Maintenance or Obligation to Deliver. 

 The Parties shall have no obligation to provide support or maintenance for the Licensed Materials, including any obligation to update or correct such Licensed Materials. The Parties shall have no obligation to provide copies of the Licensed
Materials (including in the case of software, any source code and object code). 
  

	4.	NO WARRANTIES 

 THE LICENSE GRANTS HEREUNDER ARE
PROVIDED “AS-IS” WITH NO WARRANTIES, AND THE PARTIES EXPRESSLY EXCLUDE AND DISCLAIM ANY WARRANTIES UNDER OR ARISING AS A RESULT OF THIS AGREEMENT, WHETHER EXPRESS, IMPLIED OR STATUTORY, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, NON-INFRINGEMENT OR ANY OTHER WARRANTY WHATSOEVER. 
  

	5.	LIMITATIONS OF LIABILITY 

  

	 	(a)	MSCI agrees that neither MS nor its affiliates or subsidiaries (other than MSCI) (collectively, the “MS Provider Group”) and the respective directors, officers, agents,
and employees of the MS Provider Group shall have any liability, whether direct or indirect, in contract or tort or otherwise, to MSCI for or in connection with this Agreement or the transactions contemplated hereby or any actions or inactions by or
on behalf of the MS Provider Group in connection with this Agreement and such transactions. 

  

	 	(b)	 MS agrees that neither MSCI nor its subsidiaries (collectively, the “MSCI Provider Group”) and the respective directors, officers, agents, and employees
of the MSCI Provider Group shall have any liability, whether direct or indirect, in contract or tort or 

  

 2 

	 	 
otherwise, to MS for or in connection with this Agreement or the transactions contemplated hereby or any actions or inactions by or on behalf of the MSCI
Provider Group in connection with this Agreement and such transactions. 

  

	 	(c)	Notwithstanding the provisions of Section 5(a) and (b), none of the members of the MS Provider Group and the MSCI Provider Group shall be liable for any special, indirect,
incidental, consequential or punitive damages of any kind whatsoever in any way due to, resulting from or arising in connection with the performance of or failure to perform MS’s or MSCI’s obligations under this Agreement. This disclaimer
applies without limitation (i) to claims for lost profits, (ii) regardless of the form of action, whether in contract, tort (including negligence), strict liability, or otherwise, and (iii) regardless of whether such damages are
foreseeable or whether any member of the MS Provider Group or the MSCI Provider Group has been advised of the possibility of such damages. 

  

	 	(d)	In addition to the foregoing, each Party agrees that it shall, in all circumstances, use commercially reasonable efforts to mitigate and otherwise minimize its damages, whether
direct or indirect, due to, resulting from or arising in connection with any failure by the other Party to comply fully with its obligations under this Agreement. 

  

	6.	MISCELLANEOUS 

  

	 	6.1	Governing Law; Jurisdiction; Dispute Resolution. 

  

	 	(a)	This Agreement shall be construed in accordance with and governed by the substantive internal laws of the State of New York. MSCI Inc. is registered to do business in New York
under the name NY MSCI Inc. 

  

	 	(b)	Any action seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be brought
in the United States District Court for the Southern District of New York or any other New York State court sitting in New York County, and each of the parties hereby consents to the jurisdiction of such courts (and of the appropriate appellate
courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such
court or that any such suit, action or proceeding which is brought in any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or
without the jurisdiction of any such court. 

  

	 	(c)	THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY. 

  

	 	6.2	Severability. 

 If any provision of this
Agreement shall be invalid or unenforceable, such invalidity or unenforceability shall not render the entire Agreement invalid. Rather, the Agreement shall be construed as if not containing the particular invalid or unenforceable provision, and the
rights and obligations of each party shall be construed and enforced accordingly. 
  

 3 

	 	6.3	Notices. 

 Any notice, instruction, direction
or demand under the terms of this Agreement required to be in writing shall be duly given upon delivery, if delivered by hand, facsimile transmission, or mail, to the following addresses: 
  

	
	To Morgan Stanley & Co. Incorporated:
	 Morgan Stanley
 1585 Broadway
 New York, NY 10036
 Attn: Martin M. Cohen, Director of Company Law

Facsimile: (212) 507-3334

	
	To MSCI:
	 MSCI Inc.
 88 Pine Street
 New York, New York 10005
 Attn: General Counsel
 Facsimile: (212) 804-2906

 or to such other addresses or telecopy numbers as may be specified by like notice to the other
party. All such notices, requests and other communications shall be deemed given, (a) when delivered in person or by courier or a courier services, (b) if sent by facsimile transmission (receipt confirmed) on a business day prior to 5 p.m.
in the place of receipt, on the date of transmission (or, if sent after 5 p.m., on the following business day) or (c) if mailed by certified mail (return receipt requested), on the date specified on the return receipt. 
  

	 	6.4	Entire Agreement. 

 This Agreement
constitutes the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements, understandings and negotiations, both written and oral, between the parties with respect to the subject matter hereof.

  

	 	6.5	Third Party Beneficiaries. 

 This Agreement
is not intended to confer upon any person or entity other than the parties hereto any rights or remedies hereunder. 
  

	 	6.6	Amendments and Waiver. 

  

	 	(a)	Any provision of this Agreement may be amended or waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each party to this
Agreement, or in the case of a waiver, by the party against whom the waiver is to be effective. 

  

	 	(b)	No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude
any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law. 

  

 4 

	 	6.7	Construction. 

 References to a
“Section” shall be references to the sections of this Agreement, unless otherwise specifically stated. The Section headings in this Agreement are intended to be for reference purposes only and shall in no way be construed to modify or
restrict any of the terms or provisions of this Agreement. 
  

	 	6.8	Counterparts. 

 This Agreement may be
executed in separate counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one agreement. 
  

 5 

 IN WITNESS WHEREOF, the parties have caused this Agreement to be signed by their duly authorized representatives.

  

									
	 Morgan Stanley & Co. Incorporated
	 		 	MSCI Inc.
					
	By:	 	  
	 		 	By:	 	  

	Printed:	 	  
	 		 	Printed:	 	  

	Title:	 	  
	 		 	Title:	 	  

		 	  
	 		 		 	  

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]